Veru reports FY2025 net loss $22.7M, cash $15.8M; enobosarm Phase 2b PLATEAU to start Q1'26

VERU INC.

Net loss from continuing ops $15.7M ($1.07/sh) vs $35.3M ($2.61/sh) prior year; total net loss $22.7M ($1.55/sh).
Post year-end public offering net proceeds ~$23.4M; cash as of Sep 30, 2025 was $15.8M vs $24.9M prior year.
FDA confirmed enobosarm 3 mg acceptable; incremental weight loss of ≥5% placebo-corrected at 52 weeks acceptable primary endpoint for approval.
Phase 2b QUALITY: enobosarm 3 mg preserved 100% lean mass, reduced physical function decline (≥10% stair climb power) from 44.8% to 17.6% with semaglutide.
Phase 2b PLATEAU of enobosarm 3 mg + GLP-1 RA in 200 obesity patients starts Q1 2026; interim results Q1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.